Trustworthy clinical practice guidelines require reliable systematic reviews of the evidence to support recommendations. Since 2016, the American Academy of Ophthalmology (AAO) has partnered with Cochrane Eyes and Vision US Satellite to update their guidelines, the Preferred Practice Patterns (PPP).
T o decide among treatment options, health care professionals benefit from consistent guidance provided in clinical practice guidelines (CPGs). 1 The Institute of Medicine standards for developing trustworthy CPGs recommend using evidence from high-quality systematic reviews to inform guideline recommendations. 1 Guideline developers can perform systematic reviews themselves, or they can partner with groups specializing in evidence synthesis. 1 The American Academy of Ophthalmology (AAO) partners with the Cochrane Eyes and Vision US Satellite (CEV@US) to update the Preferred Practice Pattern (PPP) guidelines. 2 The
Cochrane Eyes and Vision Editorial Base is located at the London School of Hygiene and Tropical Medicine in London, England. Activities based in the United States are coordinated by the CEV@US at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. The National Eye Institute has supported CEV@US since 2002. Cochrane Eyes and Vision aims to prepare and promote access to systematic reviews of interventions for preventing or treating eye conditions and/or visual impairment and helping people adjust to visual impairment or blindness. Cochrane Eyes and Vision US Satellite was tasked to identify up-to-date, reliable systematic reviews that can be used to inform the updates to the AAO PPP guidelines. In this article, we describe our experiences and findings related to identifying reliable systematic reviews that support topics of interest that were likely to be addressed in the 2016 update of the 2011 AAO PPP guidelines on cataract in the adult eye. The PPP guidelines for cataract in the adult eye were the first collaboration of this type between the AAO and CEV@US.
Methods

Eligibility Criteria
We included full-text journal articles and reports that claimed to be systematic reviews or meta-analyses anywhere in the text. We also included reports that met the definition of a systematic review or a meta-analysis when these terms were not used, as defined by the Institute of Medicine.
3 For the 2016 AAO PPP guidelines for cataract in the adult eye, a systematic review was selected and evaluated when it addressed interventions for treating cataract and could be mapped to 1 of the 24 management categories covered in the Management section of the table of contents of the previous version of the guidelines, the 2011 AAO PPP guidelines for cataract in the adult eye (eTable 1 in the Supplement). The Management section was broadly divided into Nonsurgical Management and Surgical Management.
Search
Cochrane Eyes and Vision US Satellite maintains a database of systematic reviews and meta-analyses in vision research and eye care in EndNote (Clarivate Analytics). The initial search for systematic reviews was conducted in March 2007; the search was updated in September 2009 , April 2012 , May 2014 , and March 2016 (full search strategy available in eMethods in the Supplement). 4, 5 For systematic reviews retrieved up to the 2012 search, 2 people independently identified eligible cataract reviews from the search results. For systematic reviews retrieved in 2014 and 2016 searches, 1 person (Y.C. in 2014 and A.G. in 2016) identified eligible cataract reviews; eligibility was verified by a senior member of the team (B.S.H.). Differences of opinion were resolved through discussion or by a third team member when necessary.
Mapping Systematic Reviews to the Management Categories
We mapped each relevant systematic review to 1 or more management categories listed in the Management section of the table of contents of the 2011 AAO PPP guidelines. A systematic review could be mapped to multiple categories. One person (A.G.) initially mapped all reviews; a senior member of the team (B.S.H.) verified the mapping. Differences of opinion were resolved through discussion.
Data Extraction and Assessment of Reliability of Systematic Reviews
a comprehensive literature search for eligible studies, (3) assessed risk of bias of included studies, (4) used appropriate methods for meta-analyses if meta-analysis was reported, and (5) drawn conclusions that were supported by the review findings. Definitions of the reliability assessment criteria are given in Table 1 . 8, 9, 14, 16 We considered a systematic review unreliable when 1 or more of these criteria were not met. Our classifications were based on the methods reported in the review; we did not contact review authors to obtain additional information regarding our assessment criteria.
Analysis
We tabulated the characteristics and our reliability classification of the eligible reviews. We compared review characteristics and the reliability assessment for systematic reviews published in the Cochrane Database of Systematic Reviews (Cochrane reviews) with those of systematic reviews published elsewhere (non-Cochrane reviews).
Inclusion of Reliable Systematic Reviews in the Guidelines
We sent citations for all reliable systematic reviews, mapped to the Management section of the table of contents of the 2011 AAO PPP guidelines, along with characteristics of the reliable reviews to the AAO PPP cataract panel in February 2016 and an updated list in June 2016. After publication of the 2016 AAO PPP guidelines in October 2016, 2 we examined whether the reliable systematic reviews we contributed were referenced in the 2016 AAO PPP guidelines. For comparison, we assessed whether the reliable systematic reviews published before February 2010, the last search date of the 2011 AAO PPP guidelines, had been referenced in the 2011 AAO PPP guidelines, which were developed without the same degree of CEV@US participation.
Results
Characteristics of Included Systematic Reviews
Of 1863 systematic reviews on eyes and vision in our database as of March 2016, we identified 99 that evaluated management strategies for cataract in the adult eye and were eligible for this project ( Figure 1) . The earliest review was published in 1994, but more than half were published after 2012 ( Table 2) . Twenty of 99 reviews (20%) were published by CEV authors in The Cochrane Database of Systematic Reviews. 20, 22, 27, 30, 39, 41, 44, 45, 50, 52, 60, 64, 67, 75, 80, 87, 88, 93, 98, 111 Of the 79 non-Cochrane reviews, 17-19,21,23-26,28,29,31-38, 40,42,43,46-49,51,54-59,61-63,65,66,68-74,76-79,81-86,89-92,94-97,99-110,112-115 50 (63%) were published in specialty medical journals (eg, Ophthalmology). Intraocular lenses (IOL) implantation was the most commonly examined intervention (25 of 99 [25%]), followed by phacoemulsification (20 of 99 [20%] ). In terms of outcomes, 59 of 99 reviews (60%) assessed visual acuity and 53 (54%) examined safety ( Table 2) .
Assessment of Reliability of Included Systematic Reviews
Of the 99 systematic reviews assessed, 46 (46%) were classified as reliable, and the remaining 53 (54%) were classified as unreliable ( Figure 2 and eTables 2 and 3 in the Supplement). Most of the unreliable systematic reviews (43 of 53 [81%]) fell short of more than 1 reliability assessment criterion (eTable 3 in the Supplement). Lack of reporting a comprehensive search (38 of 53 [71%] ) was the most frequent reason for classifying a systematic review as unreliable. Concordance between review findings and conclusions
Conclusions of the review were consistent with valid findings, provided a balanced consideration of benefits and harms, and did not favor a specific intervention despite lack of evidence.
8 Figure 1 . Identification of Cataract Systematic Reviews of the Management of Cataract in the Adult Eye 2012 (1994-2016) 2013 (1998-2015) 2012 (1994-2016) Eligibility Criteria (Table 2) . Thirty-nine reviews (38%) reported government funding, and 18 reviews (18%) reported foundation funding. Only 5 reviews (5%) reported receiving funding from industry. The median number of studies included in these systematic reviews was 12 (interquartile range, 7-25). Fifty-eight reviews (59%) reported on the number of participants included, and 17 reviews (17%) reported on the number of eyes included. Among reviews reporting on the number of participants and eyes, the median numbers included were 1313 (interquartile range, 655-4292) and 1573 (interquartile range, 722-3800), respectively. Compared with reliable systematic reviews, unreliable reviews less often had been developed with government funding (16 [30%] vs 23 [50%] ) and more often with funding from industry (5 [9%] vs 0%) ( Table 2 ). All 20 Cochrane reviews were classified as reliable; they accounted for 43% (n = 20) of all reliable reviews. Compared with nonCochrane reviews, Cochrane reviews more often had 2 or more review authors who independently selected studies, assessed risk of bias, and extracted data. Neither Cochrane nor non-Cochrane reviews scored well with respect to discussing limitations of the review at the review level (eg, b The denominator was 92 for systematic reviews with defined eligibility criteria.
c The denominator was 54 for systematic reviews reporting 2 or more title/abstract screeners.
d The denominator was 50 for systematic reviews reporting 2 or more methodologic quality assessors.
e The denominator was 56 for systematic reviews reporting 2 or more data abstractors.
f The denominator was 97 for systematic reviews including at least 1 primary study.
g The denominator was 59 for systematic reviews reporting at least 1 meta-analysis. a Systematic reviews may be counted in more than 1 category, so totals may add to more than 100%.
incomplete retrieval of relevant studies, the potential effect of reporting bias on the review findings) (eFigure in the Supplement).
Observations Regarding the Reliable Systematic Reviews visual acuity. We provided the AAO with both reviews so that the panelists could decide whether and how the discordant findings affected their recommendations.
Inclusion of Reliable Systematic Reviews in the 2016 AAO PPP Guidelines
We sent references for the reliable systematic reviews to the AAO cataract guideline panel for use in updating the 2016 AAO PPP guidelines for cataract in the adult eye. These reviews were mapped to 18 of the 24 management categories (75%) of the table of contents of the 2011 AAO PPP guidelines. We did not identify any reliable systematic review for 6 of the 24 management categories (25%): indications for surgery, contraindications to surgery, biometry and IOL power calculation, toxic anterior segment syndrome, cataract surgery checklist, and discharge from surgical facility. There may be a need for randomized clinical trials and systematic reviews in these areas (eTable 4 in the Supplement). We identified reliable systematic reviews for 2 topics that were not covered in the 2011 AAO PPP guidelines: prophylaxis for cystoid macular edema after cataract surgery 90, 94, 104, 109 and timing for cataract surgery. 38, 54 All 46 reliable systematic reviews were cited in the 2016 AAO PPP guidelines. In contrast, before the close partnership between CEV@US and AAO was established, only 8 of 15 reliable systematic reviews (53%) available at that time were cited in the 2011 AAO PPP guidelines. Although CEV@US has never sent unreliable systematic reviews to the AAO PPP panel, we noticed that the 2016 AAO PPP guidelines cited 16 unreliable systematic reviews in various contexts. Two unreliable systematic reviews were used to inform treatment recommendations.
51,113
Discussion
We contributed 46 reliable systematic reviews, nearly half of all 99 eligible reviews we had identified, to the guideline panel charged with preparing the 2016 update of the AAO PPP guidelines on the management of cataract in the adult eye. Most of the unreliable reviews fell short on more than 1 methodologic criterion. No evidence of a comprehensive literature search was the most common reason for classifying a review as unreliable. Cochrane reviews constituted a fifth of all identified reviews and were all classified as reliable. Achieving evidence-based health care involves an intense effort. First, evidence must be generated, and then the available evidence must be synthesized in a reliable way. Synthesized evidence must be further translated into policy, often manifested as evidence-based CPGs. Finally, the policy must be applied for the evidence to have an effect on care. It takes a coordinated effort among stakeholders to achieve the collective needs of patients, caregivers, and policy makers. Collaboration between systematic reviewers and guideline developers is necessary to target important topics to be addressed in systematic reviews and to improve the trustworthiness and validity of CPGs, 1 as evidenced by the increased reference to reliable evidence in the 2016 AAO PPP guidelines. This close collaboration facilitates active dissemination of systematic review findings. We believe our approach of working directly with guideline developers aligns well with the 5 core areas for change outlined in the 2016 National Academies of Science, Engineering, and Medicine report Making Eye Health a Population Health Imperative: Vision for Tomorrow, specifically, generating evidence to guide policy decisions and evidence-based actions.
116
As a result of this project, we identified 6 topics without a reliable published systematic review. Treatment recommendations in these management categories were made on the basis of the findings from individual studies or expert consensus. While some of the studies that supported treatment recommendations were well-designed and widely known randomized clinical trials, reliable systematic reviews of data available from all studies that have addressed the same research question offer a more comprehensive and compelling evidence base than individual studies. Furthermore, systematic reviews are particularly useful for evaluating consistency of findings across all studies of the same research question and for studying outcomes that are rare (eg, adverse events).
117 Future collaborations between clinical researchers, CEV@US, and AAO could focus on important clinical questions in which there are a need for evidence generation and/or synthesis. Our use of the word reliable refers to the reliability of the methods used by the systematic reviewers. The criteria we used to categorize reliable reviews were based on the standards set by the Institute of Medicine and the Methodological Expectations of Cochrane Intervention Reviews.
3,15 However, our criteria were more modest than these standards as we used only a few important items from the full set of recommendations for assessing the reliability of reviews. Consistent with our previous work on glaucoma and age-related macular degeneration 7, 8 and work in other areas, [118] [119] [120] [121] we found that a large proportion of published systematic reviews were redundant and unreliable. This constitutes a form of research waste. 122 To ensure the pro- duction of reliable systematic reviews, methodologic and reporting standards must be followed. Other considerations include ensuring that systematic reviews are conducted by individuals with adequate training, and that reports of systematic reviews are reviewed by peer reviewers and editors knowledgeable in methods and reporting standards for systematic reviews. 123 Cochrane Eyes and Vision is partnering with 10 major vision science journals, whereby a CEV methodologist serves as an editor for systematic review manuscripts submitted for publication.
124
We believe that reliable reviews are more likely than unreliable reviews to be reproducible and provide highquality summarized findings from research. The Institute of Medicine recommends that CPGs be based on high-quality systematic reviews.
1 These reviews may be de novo reviews conducted or contracted by the guideline developers or already existing reviews. Although developers may want to conduct a new systematic review to ensure inclusion of the most up-to-date primary research or to address the questions deemed most important for the CPG, it may not be efficient or necessary to conduct a new review given the amount of primary literature to be examined for each review. Because most CPGs address a variety of clinically distinct scenarios, it would be an enormous undertaking to conduct a new systematic review for each clinical question, an undertaking likely impossible to complete within realistic time frames. For example, the AAO cataract PPP guidelines address a diverse number of questions, including nonsurgical management, surgical management, and anesthesia for surgery. 3 In such cases, it may be preferable to use reliable existing reviews to inform recommendations, as the PPP panel did, and only conduct new systematic reviews of the primary literature when there are no existing reviews or the existing review is dangerously out-of-date.
Strengths and Limitations
Our investigation had strengths. The database of systematic reviews and meta-analyses in vision research and eye care was not compiled specifically for the purpose of informing the AAO panel charged with updating the PPP guidelines for management of cataract in adult eyes or any other team of CPG developers. It was assembled, updated, and coded to cover a broad range of eye and vision conditions and to serve researchers and users with diverse interests. Coding of reviews by condition and by area of relevance to cataract management was performed independently by 2 or more members of CEV. Our investigation also has limitations. First, we limited our investigation to systematic reviews published in English and Chinese, which 1 or more of us could read. We did not translate articles written in other languages. In addition, application of our reliability criteria was subjective and may have reflected our connections to Cochrane.
Conclusions
In conclusion, the collaboration between CEV@US and AAO is a positive step toward identifying reliable systematic reviews and using them to inform guideline recommendations. The increased proportion of available and reliable systematic reviews cited by the AAO panel between the 2011 and 2016 versions of the cataract PPP guidelines demonstrated the success of this close interaction between guideline developers and systematic review groups, as emphasized by the Institute of Medicine. We look forward to continuing and expanding this partnership, to partnering with others responsible for developing CPGs and formulating policy, and to identifying areas in need of evidence generation and synthesis.
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Critical Appraisal Skills Programme (CASP).
EMBASE search strategies
((*'asthenopia'*/de OR *'asthenopia'*) OR (*'cerebral blindness'*/de OR *'cerebral blindness'*) OR (*'diplopia'*/de OR *'diplopia'*) OR (*'eye malformation'*/de OR *'eye malformation'*) OR (*'eye burn'*/de OR *'eye burn'*) OR (*'eye injury'*/de OR *'eye injury'*) OR (*'perforating eye injury'*/de OR *'perforating eye injury'*) OR (*'hemianopia'*/de OR *'hemianopia'*) OR (*'lacrimal gland disease'*/de OR *'lacrimal gland disease'*) OR (*'intraocular hypotension'*/de OR *'intraocular hypotension'*) OR (*'photophobia'*/de OR *'photophobia'*) OR (*'pupil disease'*/de OR *'pupil disease'*) OR (*'sclera disease'*/de OR *'sclera disease'*) OR (*'scotoma'*/de OR *'scotoma'*) OR (*'vitreoretinopathy'*/de OR *'vitreoretinopathy'*) OR (*'vitreous body detachment'*/de OR *'vitreous body detachment'*) OR (*'transitional blindness'*/de OR *'transitional blindness'*) OR (*'amblyopia'*/de OR *'amblyopia'*) OR (*'blindness'*/de OR *'blindness'*) OR (*'color vision defect'*/de OR *'color vision defect'*) OR (*'conjunctiva disease'*/de OR *'conjunctiva disease'*) OR (*'cornea disease'*/de OR *'cornea disease'*) OR (*'eye disease'*/de OR *'eye disease'*) OR (*'intraocular foreign body'*/de OR *'intraocular foreign body'*) OR (*'intraocular hemorrhage'*/de OR *'intraocular hemorrhage'*) OR (*'eye infection'*/de OR *'eye infection'*) OR (*'eye tumor'*/de OR *'eye tumor'*) OR (*'eyelid disease'*/de OR *'eyelid disease'*) OR (*'lens disease'*/de OR *'lens disease'*) OR (*'night blindness'*/de OR *'night blindness'*) OR (*'intraocular hypertension'*/de OR *'intraocular hypertension'*) OR (*'eye movement disorder'*/de OR *'eye movement disorder'*) OR (*'optic nerve disease'*/de OR *'optic nerve disease'*) OR (*'orbit disease'*/de OR *'orbit disease'*) OR (*'refraction error'*/de OR *'refraction error'*) OR (*'retina disease'*/de OR *'retina disease'*) OR (*'uvea disease'*/de OR *'uvea disease'*) OR (*'visual disorder'*/de OR *'visual disorder'*)) AND ((*search*) OR (*'meta analysis'* OR *'systematic review'*)) eTable 1. 2011 Academy for Ophthalmology (AAO) Preferred Practice Patterns (PPP) • There is contradictory evidence about the effect of cataract surgery on the development or progression of age-related macular degeneration (ARMD).
• Expedited phaco extracapsular extraction may be more effective at improving visual acuity compared with waiting list control in people with cataract without ocular comorbidities.
• Manual large-incision extracapsular extraction has also been shown to be successful in treating cataracts.
• Intracapsular extraction is likely to be better at improving vision compared with no extraction, although it is not as beneficial as manual (large or small) incision extracapsular extraction. The rate of complications is also higher with this technique compared with extracapsular extraction.
• In people with glaucoma and cataract, concomitant cataract surgery (phaco or manual large-incision extracapsular extraction) and glaucoma surgery seems more beneficial than cataract surgery alone, in that they both improve vision to a similar extent, but the glaucoma surgery additionally improves intraocular pressure.
Performing procedures in the order of cataract surgery first followed by pan retinal photocoagulation may be more effective than the opposite order at improving visual acuity and reducing the progression of diabetic macular oedema in people with cataract and diabetic retinopathy secondary to type 2 diabetes. However, these results come from one small RCT.
• One of the possible harms of cataract surgery is cystoid macular "It is therefore our view that much more research will need to be conducted before anything conclusive can be asserted with respect to the effects of omega-3 fatty acids on eye health. It is also our understanding that sorting out the possible benefits of the intake of omega-3 fatty acids in eye health might profit from taking into consideration the impact of the concurrent intake of omega-6 fatty acids and, by definition, the omega-6/omega-3 fatty acid intake ratio. Patients with chronic aphakic and pseudophakic CME Medical prophylactic intervention "A combination of the results from RCTs indicates that medical prophylaxis for aphakic and pseudophakic CME and medical treatment for chronic CME are beneficial. Because most of the RCTs performed to date have problems related to quality, a welldesigned RCT is needed to confirm this result, using clinical CME and vision as outcomes." Interventions for prophylaxis of CME "Topical NSAIDs significantly reduced the odds of developing CME, as compared to topical corticosteroids, in nondiabetic and mixed populations. A combination of topical NSAIDs and corticosteroids reduced the odds of developing CME in nondiabetic and diabetic patients, as compared to topical corticosteroids" The denominator was 20 for Cochrane and 72 for non-Cochrane systematic reviews with defined eligibility criteria b The denominator was 19 for Cochrane and 35 for non-Cochrane systematic reviews reporting two or more title/abstract screeners c The denominator was 16 for Cochrane and 34 for non-Cochrane systematic reviews reporting two or more methodologic quality assessors d The denominator was 18 for Cochrane and 38 for non-Cochrane systematic reviews reporting two or more data abstractors e The denominator was 18 for Cochrane and 79 for non-Cochrane systematic reviews including at least one primary study f The denominator was 11 for Cochrane and 48 for non-Cochrane systematic reviews reporting at least one meta-analysis Five criteria used for classifying reliability of systematic reviews
